GSK nears deadline on Currabinny plant in Cork

GSK nears deadline on Currabinny plant in CorkPharmaceutical major, GlaxosmithKline is nearing a deadline set by the US Food and Drug Administration to ensure the regulator on quality standards at its Currabinny plant in Cork.

The regulator had set the deadline for the company to explain how it intends to comply with the rules set by the authorities. The recent letter issued by the US regulator was a setback for the company's reputation as the company focuses greatly on its supply chain and establishments linked to its global network.

An inspection by the US authorities had found paroxetine, which is an active ingredient in popular antidepressants Paxil and Seroxat, which might have been contaminated. The issue was noted in the previous year but GSK's remedial actions were considered insufficient in March and the authority issued the warning letter.

Andrew Whitty and his management team are working to repair their relationship with the authorities in another major market, China. The company is working to increase its business in emerging markets and its business in China is a major part of this strategy. The company faces allegations of bribery and corruption in China. The company also faces allegations of bribery in Iraq and is now working to revive its reputation in the market.